Nonprofit Exclusive Buyer Agent Organization Advises Home

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Nonprofit Exclusive Buyer Agent Organization Advises Home Buyers How to Comparison Shop Buyer Agent Fees, Commissions and Referrals

AVONDALE, Ariz., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Most of the time, home buyers do not need to pay their agent a fee out-of-pocket since normally it is built-in to the price of the home, but that doesn't mean the fee is unimportant. The National Association of Exclusive Buyer Agents (NAEBA) offers the following shopping tips on fees, commissions and referrals for home buyers.

Find out about the buyer agent's fees upfront and get it in writing. - In a typical real estate transaction with two agents, the commission is split. There are times, however, when the buyer's agent may have agreed to a different fee. In rare cases or in cases where the seller does not have an agent, arrangements may have to be made for agent compensation. The buyer should find out in advance what the agent's compensation is so that prices can be compared.

Buyers should not count on being able to negotiate a lower fee but can shop around for one. – There is not a "standard fee" in real estate. Buyer agents each set their own fees just as other professionals like doctors and lawyers do. If an agent does agree to negotiate a lower fee from what was originally quoted, many factors are considered including the price of the home, the expected length of the home search, the type of financing being used for the purchase, having a previous relationship with the buyer, and the agent's expenses. Keep in mind that just as fees vary from agent to agent, so can the services offered. Be sure to compare apples to apples when shopping and ask if the agent will remain on your side no matter which home you purchase or if they will ask you to agree to lesser representation.

Sometimes a buyer agent will pay a referral fee for a relocating home buyer. - According to NAEBA President Dawn Rae, "Referral services can be a great way for a buyer to find the right buyer agent, but they may affect the compensation or even the willingness of the buyer agent to work with a particular buyer." These referral fees, which can only be paid to other licensed brokerages, not to a consumer, have been recorded as high as 40% of the agent's commission. Buyers' agents consider this a marketing cost and simply a cost of doing business so it generally does not affect the fee a buyer pays, but some brokerages will refuse to pay referral fees to outside referring services they consider to be excessive. Adds Rae, "Even though NAEBA collects referral fees through its for-profit subsidiary to fund its mission of protecting home buying consumers, the referral fee is kept lower than the rest of the industry so that participating buyer agents are willing to work with all buyers."

It's important that home buyers interview several agents and get all the facts before selecting one. Home buyers can visit www.naeba.org for more information and tips.

About NAEBA

The National Association of Exclusive Buyer Agents (NAEBA), created in 1995, is an organization of companies dedicated to representing only buyers of real estate. NAEBA member brokerages do not list homes for sale and never represent sellers. This restriction to one side of the real estate transaction avoids conflicts and ensures that the interest of the homebuyer is protected at all times from house-hunting and negotiation to inspection, financing and closing.

Kimberly Kahl, CAE NAEBA Executive Director 623-932-0098

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 30

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 25

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 45

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 59

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 41

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 38

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 34

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading

Top 5 Most Recently Viewed Articles

Genesys Celebrates Global Recognition as a Top Workplace

Updated Category News Views 50

Genesys Achieves Global Recognition for Workplace Excellence Genesys, a renowned leader in AI-driven experience orchestration, has been proudly certified as a Great Place to Work. This significant accomplishment reflects the overwhelming sentiment from its employees, with a remarkable 90% affirming that Genesys is indeed a fantastic workplace. This statistic represents a...

Continue Reading
Class Action Alert for Twitter Stockholders: Important Updates

Updated Category News Views 198

Understanding the Class Action Lawsuit for Twitter, Inc. Stockholders A significant class action lawsuit has been initiated for individuals and entities who traded Twitter, Inc. stock or options during a specified period. This legal action has garnered substantial attention as it affects numerous investors who believe they suffered losses due to alleged misconduct. Key...

Continue Reading
Rhythm Pharmaceuticals Advances IMCIVREE® for Young Patients

Updated Category News Views 180

Rhythm Pharmaceuticals Receives FDA Acceptance for Priority Review Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company, has announced that the FDA has accepted its supplemental New Drug Application (sNDA) for IMCIVREE® (setmelanotide). This application has been designated for Priority Review by the FDA, which suggests that patients may gain timely...

Continue Reading
Understanding Market Trends Impacting NCR Atleos Corp's Future

Updated Category News Views 59

Market Sentiment Surrounding NCR Atleos Corp NCR Atleos Corp (NYSE: NATL) has recently caught the attention of investors as its short interest percentage has experienced a notable increase. Currently, approximately 3.76% of the company's shares have been sold short, which translates to about 3.01 million shares. This figure indicates that roughly 6.35% of all regular...

Continue Reading
Leslie’s, Inc. Reports Q2 Fiscal 2025 Earnings and Key Insights

Updated Category News Views 346

Financial Highlights from Leslie’s, Inc. In light of recent developments, Leslie’s, Inc. (NASDAQ: LESL), the premier name in pool and spa care in the U.S., has unveiled its financial results for the second quarter of fiscal year 2025. The company is dedicated to serving both residential and professional customers with quality products and exceptional service. CEO...

Continue Reading